AbbVie (AbbVie) GF Value : $137.90 (As of Apr. 27, 2024)

View and export this data going back to 2012. Start your Free Trial

What is AbbVie GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-27), AbbVie's share price is $159.62. AbbVie's GF Value is $137.90. Therefore, AbbVie's Price-to-GF-Value for today is 1.16.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes AbbVie is Modestly Overvalued.

AbbVie (NYSE:ABBV) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

AbbVie's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	159.62	/	137.90
	=	1.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie GF Value Related Terms

Thank you for viewing the detailed overview of AbbVie's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (AbbVie) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB0:Germany 4AB:Germany 4AB:Germany 4AB:Germany ABBV:Canada ABBV34:Brazil ABBV:Austria

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Executives

Nicholas Donoghoe	officer: SVP, Enterprise Innovation	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin	director	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis	director	1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez	officer: Chairman of the Board and CEO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg	officer: Sr. V.P., U.S. Commercial Ops.	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis	officer: EVP, GC and Secretary	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart	officer: SVP, US Commercial Operations	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee	officer: SVP, Controller	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents	officer: SVP, Chief Financial Officer	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt	officer: SVP, Operations	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom	officer: SVP & Pres Global Allerg Aesth	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin	director	200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond	officer: EVP, Chief HR Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino	officer: EVP, R&D and CSO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch	officer: Chief Strategy Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092